此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

2021年6月22日 更新者:Shire

A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics, Safety, and Tolerability of SSP-004184 (SPD602) in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects

The purpose of this study is to evaluate how much of the study drug SSP-004184 (SPD602) is absorbed by the body and how long it takes to be eliminated from the body in healthy subjects and subjects with mild, moderate, and severe hepatic (liver) impairment compared with subjects with healthy normal liver function.

研究概览

地位

完全的

干预/治疗

研究类型

介入性

注册 (实际的)

44

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Florida
      • Miami、Florida、美国、33014
        • Clinical Pharmacology of Miami
      • Orlando、Florida、美国、32809
        • Orlando Clinical Research Center (OCRC)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 18-65 years inclusive at the time of consent.
  • Willingness to comply with any applicable contraceptive requirements of the protocol and is:
  • Male, or
  • Non pregnant, non lactating female
  • Females must be at least 90 days post partum or nulliparous.

Subjects who do not have hepatic impairment (healthy subjects)

  • Normal renal function.

Subjects with hepatic impairment

  • Subjects must provide a letter of evaluation from a hepatologist or copy of supporting documents confirming the subject's hepatic impairment (a liver biopsy is preferable but not mandatory).
  • Hepatic impairment should be primary and must not be a complication of an underlying primary systemic disease (eg, patients with metastatic cancer and cancer cachexia)
  • Documented chronic stable liver impairment

Exclusion Criteria

Subjects who do not have hepatic impairment (healthy subjects)

  • A positive HIV antibody screen, Hepatitis B surface antigen, or Hepatitis C virus antibody screen.

Subjects with hepatic impairment

  • Presence of a hepatocellular carcinoma, or an acute hepatic disease caused by an infection or drug toxicity.
  • Presence of surgically created or transjugular intrahepatic portal systemic shunts.
  • A positive HIV antibody screen.
  • Renal insufficiency.

All subjects

  • Subject has a history of thyroid disorder.
  • History of nephrotic syndrome.
  • History of alcohol or other substance abuse within the last year.
  • A positive screen for alcohol or drugs of abuse.
  • Male subjects who consume more than 3 units of alcohol per day. Female subjects who consume more than 2 units of alcohol per day. (1 alcohol unit = 1 beer [12 oz/355 mL] = 1 wine [5 oz/150 mL] = 1 liquor [1.5 oz/40 mL] = 0.75 oz/20 mL alcohol.)
  • Caffeine consumption: For healthy subjects: Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches or have a history of caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6 oz/180 mL cup of coffee, two 12 oz/355 mL (ie, 24 oz/710 mL cola) cans of cola, one 12 oz/355 mL cup of tea, three 1 oz/28 g chocolate bars (ie, 3 oz/85 g chocolate). Decaffeinated coffee, tea, or cola are not considered to contain caffeine.)
  • Donation of blood or blood products within 60 days.
  • Substantial changes in eating habits within 30 days.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:SSP-004184 (Child-Pugh A Liver Impaired)
The Child-Pugh Score is a scoring system used to determine the prognosis with cirrhosis and need for liver transplantation. Scoring is based upon albumin, ascites, total bilirubin, prothrombin time, and encephalopathy. Each category is based on a scoring system of 1-3 with 3 being the worst and a total score range of 5-15. It is broken into categories A (score of 5-6), B (score of 7-9), and C (score of 10-15) with worsening from A to C for prognosis.
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
其他名称:
  • SPD602, FBS0701
实验性的:SSP-004184 (Child-Pugh B Liver Impaired)
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
其他名称:
  • SPD602, FBS0701
实验性的:SSP-004184 (Child-Pugh C Liver Impaired)
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
其他名称:
  • SPD602, FBS0701
实验性的:SSP-004184 (Matched Healthy Subjects)
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
其他名称:
  • SPD602, FBS0701

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
SSP-004184 的血浆浓度-时间曲线下面积 (AUC)
大体时间:给药后超过 96 小时
AUC 可用作药物暴露的量度。 它源自药物浓度和时间,因此可以衡量药物在体内停留的时间和数量。
给药后超过 96 小时
SSP-004184 的最大血浆浓度 (Cmax)
大体时间:给药后超过 96 小时
Cmax 是指药物给药后在体内达到的最大(或峰值)浓度的术语。
给药后超过 96 小时
Time of Maximum Plasma Concentration (Tmax) for SSP-004184
大体时间:Over 96 hours post-dose
Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.
Over 96 hours post-dose
Plasma Half-Life (T 1/2) of SSP-004184
大体时间:Over 96 hours post-dose
The time it takes for the blood plasma concentration of a substance to halve.
Over 96 hours post-dose
Total Body Clearance (CL/F) of SSP-004184
大体时间:Over 96 hours post-dose
The rate at which a drug is removed from the body.
Over 96 hours post-dose
Volume of Distribution (Vz/F) of SSP-004184
大体时间:Over 96 hours post-dose
The distribution of a medication between plasma and the rest of the body.
Over 96 hours post-dose

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2012年11月9日

初级完成 (实际的)

2013年4月1日

研究完成 (实际的)

2013年4月1日

研究注册日期

首次提交

2012年11月19日

首先提交符合 QC 标准的

2012年11月21日

首次发布 (估计)

2012年11月22日

研究记录更新

最后更新发布 (实际的)

2021年7月19日

上次提交的符合 QC 标准的更新

2021年6月22日

最后验证

2021年6月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • SPD602-105

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

SSP-004184的临床试验

3
订阅